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Telomerase is a ribonucleoprotein reverse transcriptase that extends the ends of chromosomes. The two
telomerase subunits essential for catalysis in vitro are the telomerase reverse transcriptase (TERT) and the
telomerase RNA. Using truncations and site-specific mutations, we identified sequence elements of TERT and
telomerase RNA required for catalytic activity and protein-RNA interaction for Tetrahymena thermophila telomerase. We found that the TERT amino and carboxyl termini, although evolutionarily poorly conserved, are nonetheless important for catalytic activity. In contrast, high-affinity telomerase RNA binding requires only a small
region in the amino terminus of TERT. Surprisingly, the TERT region necessary and sufficient for telomerase
RNA binding is completely separable from the reverse transcriptase motifs. The minimal Tetrahymena TERT
RNA binding domain contains two sequence motifs with ciliate-specific conservation and one TERT motif with
conservation across all species. With human TERT, we demonstrate that a similar region within the TERT
amino terminus is essential for human telomerase RNA binding as well. Finally, we defined the Tetrahymena
telomerase RNA sequences that are essential for TERT interaction. We found that a four-nucleotide region 5ⴕ
of the template is critical for TERT binding and that the 5ⴕ end of telomerase RNA is sufficient for TERT
binding. Our results reveal at least one evolutionarily conserved molecular mechanism by which the telomerase
reverse transcriptase is functionally specialized for obligate use of an internal RNA template.
cific features of activity such as nucleotide and repeat addition
processivities. These results suggest that the RNA plays roles
in addition to simply providing the template sequence. Ciliate
telomerase RNAs have limited primary sequence homology
but do share elements of evolutionarily conserved secondary
structure (20, 22, 23, 29).
Only one protein, the telomerase RT (TERT), is known to
be common to telomerase RNPs of all species (reviewed in
reference 4). The central region of the TERT polypeptide
contains RT active site motifs which are essential for activity
in vivo and in vitro (21, 33). Aside from these RT motifs, only
limited patches of TERT-specific sequence similarity have
been identified (6, 24, 28, 34). It is possible to assemble an active recombinant telomerase RNP containing only TERT and
telomerase RNA, bypassing the cellular requirement for other
telomerase proteins and a specific telomerase RNP assembly
pathway (reviewed in reference 9). Expression of TERT and
telomerase RNA from human, mouse, or the ciliate Tetrahymena thermophila in rabbit reticulocyte lysate is sufficient for
telomerase activity (10, 12, 33). This catalytic core of telomerase faithfully positions the template to direct accurate telomeric repeat synthesis. Notably, the assembly of recombinant
human or Tetrahymena telomerase RNPs involves the participation of other activities in reticulocyte lysate (17, 19). Recombinant Tetrahymena telomerase RNP assembly occurs with high
specificity and is robust enough to allow detection of telomerase RNA coimmunoprecipitated with TERT (19).
Here, we have used recombinant Tetrahymena telomerase
reconstituted in rabbit reticulocyte lysate to investigate the
functional significance of regions within TERT and the telomerase RNA. We find that telomerase RNP activity in vitro
requires even the TERT extreme N and C termini, which lack
any substantial evolutionary sequence conservation. In contrast, the stable interaction of TERT and telomerase RNA

Telomeres are the structures at chromosome ends that distinguish chromosome termini from double-stranded DNA
breaks, protecting natural chromosome ends against fusion,
recombination, and degradation (reviewed in reference 35). In
most eukaryotes, telomeric DNA is composed of a tandem
array of simple sequence repeats. Some of these repeats are
lost with each round of chromosome duplication, requiring a
separate DNA synthesis mechanism to compensate for this
loss. Most commonly, this task is accomplished by the enzyme
telomerase. Telomerase is a reverse transcriptase (RT) that
can add telomeric repeats to chromosome ends de novo by
copying a template region within its integral RNA (reviewed in
reference 13). Telomerase activity is required for the sustained
growth of most single-celled eukaryotes and immortal cell
lines, including human tumor cells (15, 16, 37). Insufficient
telomerase activity induces the replicative senescence of primary human cells in culture (3) and may contribute to agedependent decreases in the renewal capacity of certain human
tissues (27).
One of the unique features of telomerase as an RT is that
the assembly of a stable ribonucleoprotein (RNP) complex is
required for polymerase activity. Thus, unlike viral RTs, telomerase recognizes a template containing RNA with sequence
specificity. The roles of the telomerase RNA component in
enzyme function have been most thoroughly studied in ciliate
telomerases (reviewed in reference 8). Template changes alter
the sequence of the synthesized telomeric repeat, as expected.
In addition, sequence substitutions both inside and outside the
template affect RNP assembly, overall activity level, and spe-

* Corresponding author. Mailing address: Department of Molecular
and Cell Biology, 401 Barker Hall, University of California, Berkeley,
CA 94720-3204. Phone: (510) 643-1598. Fax: (510) 642-6062. E-mail:
kcollins@socrates.berkeley.edu.
990

VOL. 21, 2001

TERT RNA BINDING DOMAIN

requires a surprisingly small region of the TERT N terminus,
completely separable from the RT motifs. The Tetrahymena
TERT RNA binding domain contains one motif present in all
TERTs (T motif) and two motifs that are ciliate specific (CP
and CP2 motifs). We find that a similar region of human
TERT (hTERT), preceding the RT motifs and containing the
T motif, also mediates human telomerase RNA (hTR) binding.
For the Tetrahymena telomerase RNA, TERT interaction requires only residues at the 5⬘ end of the RNA, including four
nucleotides that are predicted to be unpaired. These results
have implications for the evolution of telomerase functional
specialization and for the novel mechanism of template definition within the telomerase RNP.
MATERIALS AND METHODS
Expression constructs. N-terminal TERT truncation expression constructs
were created by PCR of the desired TERT coding region followed by cloning
into pCITE4a (Novagen). C-terminal truncation expression constructs were created by internal deletions of the N-terminally His-hemagglutinin (HA) double
epitope-tagged TERT expression construct (19), using restriction enzymes that
recognized a unique site in the plasmid polylinker and a unique internal site in
the synthetic TERT gene. Combined N- and C-terminal truncation constructs
were created by PCR of the desired coding region, followed by replacement
cloning into the His-HA double epitope-tagged TERT expression construct
digested with NdeI and BamHI.
All RNA expression constructs were designed for transcription by T7 RNA
polymerase. Expression constructs for telomerase RNAs containing nucleotide
substitutions and deletions were created from pT7159 (1) by site-specific mutagenesis of double-stranded DNA, using linear amplification with Pfu DNA
polymerase followed by parental plasmid removal with DpnI. Wild-type telomerase RNA and most telomerase RNA variants were linearized with FokI before
transcription to produce a wild-type (WT) 3⬘ end. For telomerase RNA deletion
construct 1–107, an EcoRI site was created at nucleotides (nt) 107 to 112; for
deletion construct 1–74, an EcoRI site was created at nt 70 to 75; and for deletion
construct 1–59, an XbaI site was created at nt 55 to 60. The expression construct
for the 3⬘ tagged telomerase RNA (pKW1) was created by insertion of annealed
oligonucleotides at the BamHI site of pT7159 to produce a 31-nt 3⬘ tag by
transcription after digestion with HindIII. Telomerase RNAs expressed from
pT7159 derivatives possess a 5⬘ leader of three guanosines.
Recombinant telomerase production. Rabbit reticulocyte lysate expression of
TERT polypeptides was performed in the presence of [35S]methionine following
the manufacturer’s instructions (Promega TNT). For production of RNA added
back to TERT expression lysates, transcription by purified T7 RNA polymerase
was performed in vitro using standard protocols (Stratagene). RNAs were purified by DNase I treatment, organic extraction, and precipitation. All RNAs were
examined by gel electrophoresis to confirm length and purity, and RNA concentration was determined by fluorometry and comparative dot blot hybridization.
To reconstitute a telomerase RNP by purified telomerase RNA addition, TERT
expression lysate was combined with telomerase RNA, with 10 g of bovine
serum albumin (BSA) and 10 g of tRNA or total yeast RNA, and incubated at
30°C for 30 min.
Telomerase activity assay. For each activity assay, up to 3 l of rabbit reticulocyte lysate reaction mixture containing TERT and telomerase RNA, brought to
10 l in T2MG buffer (20 mM Tris-HCl [pH 8.0], 1 mM MgCl2, 10% glycerol),
was used. Each 20-l activity assay sample also contained final concentrations of
50 mM Tris-acetate (pH 8.0), 10 mM spermidine, 5 mM ␤-mercaptoethanol, and
2 mM MgCl2 as buffer, with 200 M dTTP, 4 M unlabeled dGTP, 1 M
[32P]dGTP (800 Ci/mmol), and 1 M primer (TG)8TTG. Reaction mixtures
were incubated at 30°C for 1 h followed by phenol-chloroform extraction and
ethanol precipitation, and then product DNA was resolved in a 9% denaturing
gel (19:1 acrylamide:bis, 7 M urea, 0.6⫻ Tris-borate-EDTA).
Immunoprecipitation of Tetrahymena TERT-telomerase RNA complexes. For
HA antibody immunoprecipitation, GammaBind Protein G-Sepharose resin
(Pharmacia) was bound to HA antibody and preblocked with 20 g of tRNA or
total yeast RNA per ml and 20 g of BSA per ml in binding buffer (20 mM
Tris-HCl [pH 8.0], 1 mM MgCl2, 10% glycerol, 0.1 M NaCl). For immunoprecipitation with the TERT C-terminal antibody, the same procedure was used but
with substituted Protein A-Sepharose resin (Pharmacia) and antibody. TERT
reticulocyte lysate samples were combined with telomerase RNA, 10 g of BSA,
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10 g of total yeast RNA, and 15 l of a bead slurry in a 350-l final volume and
mixed for 1 h at room temperature or overnight at 4°C. After resin washing in
binding buffer, one-third of the sample was mixed with sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, boiled, and analyzed by electrophoresis on SDS–15% PAGE gels. The remaining two-thirds of
the sample was extracted with phenol-chloroform and precipitated with ethanol.
Purified nucleic acid was resolved by denaturing gel electrophoresis in a 6 or 9%
denaturing gel (19:1 acrylamide:bis, 7 M urea, 0.6⫻ Tris-borate-EDTA) and
transferred to Hybond N⫹ (Amersham) for hybridization analysis. The RNA
blots shown in Fig. 3 and 4B and C were probed with oligonucleotide 8: GAA
GGTTATATCAGCACTAGATTT. The RNA blots shown in Fig. 6 and 7 were
probed with oligonucleotide 11: TGACAGTTCTATTACAGATCTG. The RNA
blot shown in Fig. 4D was probed for the 3⬘ tag of the telomerase RNA with the
oligonucleotide CTACGCCCTTCTCAGAATTCAATA. The quantification of
35
S protein on SDS-PAGE gels and the quantification of RNA on RNA blots was
performed by phosphorimager (Fuji) analysis.
Immunoprecipitation of hTERT-hTR complexes. Calcium phosphate-mediated transient transfection of adenovirus-transformed human embryonic kidney
(293) cells, freeze-thaw lysis and extract preparation, total RNA preparation by
acid guanidine thiocyanate-phenol-chloroform extraction, RNA blot hybridization, immunoprecipitation on Flag antibody resin (Sigma), and hTERT immunoblots were performed as described previously (25, 27). Constructs for fulllength hTERT expression were created by subcloning a KpnI-SalI restriction
fragment containing an N-terminal Flag epitope tag into the HindIII site of
pRc/CMV (Invitrogen). The 1–656, 1–617, and 1–540 hTERT expression constructs were created by subcloning restriction fragments digested with KpnI and
XhoI, AatII, or BstYI, respectively, into the same pRc/CMV vector. The 326–631
construct was generated by PCR amplification with primers containing a 5⬘ terminal EcoRI restriction site and two 3⬘ terminal stop codons; this fragment was
subcloned in frame behind an N-terminal Flag epitope tag in the pCR3 vector
(Invitrogen).

RESULTS
N-terminally and C-terminally truncated TERTs are catalytically inactive. TERT contains seven active site motifs (1, 2,
A, B⬘, C, D, and E) (Fig. 1) that are conserved among RTs (21,
28). Based upon the presence of these conserved motifs, the
central region of the TERT polypeptide is thought to adopt a
structure similar to those of other polymerases. By analogy, the
nucleotide addition active site of TERT could be viewed as a
right hand, with finger, palm, and thumb regions surrounding
the primer-template hybrid and positioning the primer 3⬘ end
for nucleotidyl transfer. Due to the specialized features of
telomerase, TERT should also contain regions that are responsible for stable association with the telomerase RNA and for
template-independent association with primer DNA. Moreover, TERT is likely to harbor additional sites of interaction
with proteins that direct telomerase assembly, localization, and
regulation in vivo. Comparison of amino acids in TERT and
a more typical RT, human immunodeficiency virus type 1
(HIV-1) RT, illustrates that TERT has long N-terminal and
C-terminal extensions flanking the conserved RT motifs and
also a larger number of amino acids separating some motifs
(Fig. 1). Previous work (6, 24, 28, 34) has identified TERTspecific motifs in the N-terminal region that are conserved in
all TERTs (T, T2) or specifically among ciliate TERTs (CP,
CP2). These features, as well as the sequence differences in the
RT motifs, are candidates for establishing telomerase-specific
functions.
To investigate the potential functions of different regions
of TERT, we created a series of expression constructs that
progressively truncated TERT N-terminal or C-terminal sequences. As shown in Fig. 1, N-terminal truncations were made
up to motif T (to amino acid 453) and C-terminal truncations
were made through the RT motif region of the protein (to
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FIG. 1. TERT truncation mapping. TERT and HIV-1 RT proteins are indicated as rectangles with the length scaled to the number of amino
acids (amino acid numbering is shown). Evolutionarily conserved sequence motifs are shaded. Motifs 1, 2, and A to E are conserved among RTs.
In the N-terminal TERT extension, all TERTs have motifs T and T2, whereas only ciliate TERTs have motifs CP and CP2. Below the Tetrahymena
TERT structure is a summary of the N- and C-terminal truncations of TERT. Full-length TERT is 1,117 amino acids, and each TERT truncation
is designated by the numbers of its first amino acid and its last amino acid. The results of telomerase RNA binding and telomerase activity assays
performed on the N-terminal and C-terminal truncations are represented as follows. ⫹, ⬎25% of the full-length TERT level; ⫺, ⬍5% of the
full-length TERT level. The region of TERT which is required for telomerase RNA binding as defined by this truncation analysis is boxed (amino
acids 195 to 593).

amino acid 406). The N-terminal truncations were not epitope
tagged but could be immunoprecipitated using antibody raised
against a peptide of the C terminus of TERT, which has previously been shown not to interfere with telomerase activity
(10). Each C-terminal truncation was constructed with an Nterminal HA epitope tag, which has been shown to be effective
for immunoprecipitation of active recombinant TERT in vitro.
Addition of this HA epitope tag to TERT has no apparent
effect on telomerase activity or telomerase RNA binding (19).
The N-terminal and C-terminal TERT truncations were first
tested for the ability to direct telomerase nucleotide addition
activity. Following coexpression of each N-terminally or C-terminally truncated protein and telomerase RNA in rabbit reticulocyte lysate in the presence of [35S]methionine, a portion
of each protein expression reaction mixture was analyzed by
SDS-PAGE and autoradiography to quantitate the amount of
protein synthesized. Each expression reaction produced a polypeptide of the expected molecular mass, and each protein was
expressed at a comparable level (Fig. 2B). Various products
smaller than the expected size were produced in each reaction.
These small products were able to be immunoprecipitated
using antibody against the TERT C terminus but could not be
immunoprecipitated by antibody against the N-terminal epitope tag, suggesting that they are produced by translation initiation at internal ATG codons (see below). The remainder of

the lysate-expressed TERT and telomerase RNA sample was
assayed for its ability to elongate the single-stranded DNA
primer (TG)8TTG in the presence of dTTP and radiolabeled
dGTP (Fig. 2A). In a single round of template copying, telomerase will add up to six nucleotides to this primer, synthesizing a G3T2G repeat. Additional repeats of six nucleotides can
also be added without product dissociation if a product 3⬘ end
extended to the end of the template repositions at the template
start.
While full-length TERT (amino acids 1 to 1117, WT) displays strong telomerase activity (Fig. 2A, lanes 1 and 6), no
activity was detected using any of the N-terminal or C-terminal
truncations (Fig. 2A, lanes 2 to 5 and 7 to 11). The weakly
radiolabeled bands observed in the N- and C-terminal truncation lanes were observed even with the C-terminal truncation
that removed the predicted polymerase domain of TERT (Fig.
2A, lane 11) and were also observed when the telomerase
activity assay was performed on rabbit reticulocyte lysate not
expressing TERT (data not shown). An additional, less extensive N-terminal truncation which removed only the first 53
amino acids of TERT also eliminated any detectable telomerase activity (data not shown). The least extensive TERT Nand C-terminal truncations were tested in activity assays with
other primers, including an entirely telomeric sequence DNA
primer (G4T2)3 and a nontelomeric sequence primer T18 that
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and the TERT truncations (Fig. 3B, lanes 2 to 5 and 7 to 11)
were synthesized in rabbit reticulocyte lysate and immunoprecipitated at comparable levels. Each TERT truncation protein
was equally capable of being immunoprecipitated, demonstrating that all of the TERT truncations expressed were similarly
soluble.
To determine the amount of RNA associated with each
TERT truncation, nucleic acid in the remainder of the immunoprecipitated material was purified, resolved by denaturing
gel electrophoresis, and then analyzed by RNA blot hybridization (Fig. 3A). An approximately 1,000-fold excess of nonspecific competitor RNA was added to each coimmunoprecipitation reaction to inhibit nonspecific association of telomerase
RNA with the antibody resin. Alterations in the amount or
type of competitor RNA added to the binding reaction did not
strongly affect the amount of telomerase RNA coimmunoprecipitated, although a high concentration of total yeast RNA
could slightly diminish telomerase RNA binding (data not
shown).
Many of the TERT truncations, although incapable of generating a telomerase enzyme active for nucleotide addition,

FIG. 2. The N and C termini of TERT are necessary for telomerase
activity. (A) Telomerase activity assays were performed with equal
amounts (3 l) of rabbit reticulocyte lysate reaction mixtures coexpressing TERT or the TERT truncation indicated and WT telomerase
RNA. Activity was monitored by the incorporation of radiolabeled
dGTP and unlabeled dTTP to elongate the primer (TG)8TTG. (B)
Equal amounts (0.5 l) of each [35S]methionine-labeled TERT and
telomerase RNA coexpression reaction were analyzed by electrophoresis on an SDS–15% PAGE gel and subsequent autoradiography.
Protein products of intended sizes are indicated by an asterisk.

can anneal to the telomerase RNA 3⬘ of the template. No
catalytic activity was detected with the truncated TERT proteins under any reaction condition tested, despite sensitivity to
less than 1% of the WT activity level (data not shown). We
assume that many of the truncated TERT proteins are likely to
fold correctly when expressed in rabbit reticulocyte lysate
based upon their ability to bind to telomerase RNA (see below). Thus, we conclude that the extreme N and C termini of
TERT are necessary for recombinant Tetrahymena telomerase
activity despite the lack of recognizable evolutionary sequence
conservation within these regions of TERT.
The TERT N-terminal extension mediates stable association
with telomerase RNA. To identify which regions of TERT are
required for interaction with telomerase RNA, we tested the
TERT truncations using a telomerase RNA coimmunoprecipitation assay. Each TERT truncation was expressed in rabbit
reticulocyte lysate in the presence of [35S]methionine and then
mixed with telomerase RNA. The N-terminal truncations were
immunoprecipitated using an antibody raised against a TERT
C-terminal peptide (10). The HA epitope-tagged C-terminal
truncations were immunoprecipitated using HA antibody. A
portion of the immunoprecipitated material was analyzed by
SDS-PAGE and autoradiography to visualize 35S-radiolabeled
protein (Fig. 3B). Full-length TERT (Fig. 3B, lanes 1 and 6)

FIG. 3. A region within the N terminus of TERT is required for
telomerase RNA binding. Each TERT truncation was expressed in a
15-l rabbit reticulocyte lysate reaction mixture and then mixed with
20 ng of telomerase RNA. The N-terminal TERT truncations were
immunoprecipitated with TERT C-terminal antibody resin, and the
C-terminal TERT truncations (with an N-terminal HA epitope tag)
were immunoprecipitated with HA antibody resin. (A) Two-thirds of
the immunoprecipitate was analyzed for telomerase RNA. The RNA
coimmunoprecipitated with each TERT was purified and analyzed by
RNA blot hybridization. Lanes 1 and 6, full-length TERT; lanes 2 to 5,
N-terminal TERT truncations; lanes 7 to 11, C-terminal TERT truncations. (B) The remaining one-third of the immunoprecipitate was
analyzed by electrophoresis on an SDS–15% PAGE gel and subsequent autoradiography. Intended protein products are indicated by
asterisks.
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FIG. 4. Mapping of the telomerase RNA binding domain in TERT. (A) TERT structure from amino acids 200 to 600 is illustrated with the
conserved motifs in this region shaded. A summary of the 12 TERT double truncations is shown. The RNA binding domain of TERT maps to
amino acids 195 to 516. (B) The ability of full-length TERT and TERT fragments to bind to 20 ng of telomerase RNA was assayed by coimmunoprecipitation. Two-thirds of each immunoprecipitate was extracted for telomerase RNA analysis by RNA blot hybridization (top), and
one-third of each reaction mixture was analyzed for protein by SDS-PAGE and autoradiography (bottom). Different regions of the same
SDS-PAGE gel are shown for full-length TERT (marked with an asterisk) and the TERT truncations. (C) Full-length TERT (lanes 1 to 4, 1–1117)
and three TERT double truncations (lanes 5 to 8, 195–553; lanes 9 to 12, 195–516; lanes 13 to 16, 195–457) were synthesized in rabbit reticulocyte
lysate. The expression levels of all TERT constructs were approximately equal (data not shown). To each protein synthesis reaction was added 2
ng (lanes 1, 5, 9, and 13), 10 ng (lanes 2, 6, 10, and 14), or 50 ng (lanes 3, 7, 11, and 15) of WT telomerase RNA or 50 ng of a CA15-16GU
telomerase RNA variant (lanes 4, 8, 12, and 16). The RNA coimmunoprecipitated with each TERT was purified and analyzed by RNA blot
hybridization. (D) Twenty nanograms of tagged telomerase RNA and various competitors were added to N-terminally HA epitope-tagged
full-length TERT (lanes 1 to 6) or the N-terminally HA epitope-tagged RNA binding domain of TERT (lanes 7 to 12). Competitors, added as a
titration of 1-, 5-, and 25-fold the molar amount of tagged RNA, were untagged full-length telomerase RNA (lanes 1 to 3 and 7 to 9) or untagged
full-length telomerase RNA with a CA15-16GU substitution (lanes 4 to 6 and 10 to 12). The RNA coimmunoprecipitated with each TERT on HA
antibody resin was purified and analyzed by RNA blot hybridization with an oligonucleotide recognizing the 3⬘ tag of the tagged telomerase RNA.
Quantitation of competition is shown within each set relative to the lowest concentration of competitor.

retained the ability to interact with telomerase RNA (Fig. 3A).
The shortest C-terminally truncated TERT capable of binding
telomerase ends at amino acid 593 (Fig. 3A, lane 10). The
shortest N-terminal truncation capable of binding to telomerase RNA begins at amino acid 195 (Fig. 3A, lane 4). The
decreased level of RNA precipitated for TERT truncations
123–1117, 141–1117, and 195–1117 (Fig. 3A, lanes 2 to 4)
compared to that for wild-type TERT (Fig. 3A, lane 1) is
probably due to the reduced expression levels of these truncations (Fig. 3B, lanes 2 to 4). Telomerase RNA was not immunoprecipitated with the most extensive TERT truncations (Fig.
3A, lanes 5 and 11) or in samples lacking TERT (data not
shown). These results delineate a region of TERT between

amino acids 195 and 593 that is necessary for telomerase RNA
binding (Fig. 1). Surprisingly, this eliminates most of the central TERT RT motif region and therefore most of the evolutionarily conserved TERT residues.
The TERT RNA binding domain is entirely separable from
the RT motifs. To finely map the region of TERT which is
necessary for stable telomerase RNA binding, and to determine the minimum sufficient region, we created a new set of
TERT expression constructs which lacked both the TERT N
and C termini. Twelve new TERT truncations were designed
to include all combinations of proteins that begin at amino
acids 195, 224, or 240 and end at amino acids 457, 516, 553, or
593 (Fig. 4A). The locations of the start and stop sites for these
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double truncations were chosen to accomplish a fairly regular
increment of mass loss and to avoid disrupting regions of
strong sequence conservation. Each new TERT truncation,
designed to include an HA epitope tag at its N terminus, was
expressed by in vitro translation and then mixed with telomerase RNA. The interaction of TERT truncations with telomerase RNA was assayed using the same coimmunoprecipitation
protocol used for the C-terminal truncations. After purification on HA antibody resin, bound protein was analyzed by
SDS-PAGE and autoradiography (Fig. 4B). Each protein was
immunopurified with similar efficiency and migrated at approximately the expected molecular mass. Full-length TERT (amino acids 1 to 1117, WT) and the TERT truncations containing
amino acids 195 to 593, 195 to 553, and 195 to 516 were able
to immunoprecipitate telomerase RNA (Fig. 4B, lanes 2, 5,
and 8). Notably, both N-terminal truncation to amino acid 224,
up to the border of motif CP2, and truncation to amino acid
240, which completely removes motif CP2, dramatically inhibited the RNA binding activity of TERT. Motif CP2 has been
implicated in the accurate definition of the template 5⬘ end
(24). The removal of amino acids 516 to 458, a region that
contains the TERT conserved motif T, was also inhibitory for
RNA binding.
To confirm that the minimal TERT binding domain does
bind to telomerase RNA with a similar efficiency as full-length
TERT, we titrated telomerase RNA in our binding assay. After
lysate expression of TERT protein, 2, 10, or 50 ng of purified
telomerase RNA and an excess of nonspecific total yeast RNA
were added to equal volumes of the TERT expression lysates
before immunoprecipitation. We found, as before, that fulllength TERT (Fig. 4C, lanes 1 to 3) and TERT fragments
including amino acids 195 to 553 (Fig. 4C, lanes 5 to 7) or 195
to 516 (Fig. 4C lanes 9 to 11) coimmunoprecipitated telomerase RNA effectively. Removing amino acids 457 to 516 diminished RNA binding activity substantially (Fig. 4C, lanes 13 to
15).
A previous study demonstrated that a substitution of two
nucleotides, CA15-16GU, 5⬘ of the T. thermophila RNA template inhibited catalytic activity and TERT interaction (19).
We used this telomerase RNA variant to test whether the
TERT N-terminal fragments retained a binding specificity parallel to that of full-length TERT. Indeed, we found that the
CA15-16GU telomerase RNA substitution inhibited the interaction of telomerase RNA with the TERT fragments as it did
with full-length TERT (Fig. 4C, lanes 4, 8, 12, and 16). Therefore, RNA association with the minimized RNA binding domain of TERT shows the same requirement for CA15-16 as
the full-length protein.
We also demonstrated this specificity using a competition
assay rather than a direct binding assay (Fig. 4D). With fulllength TERT or the RNA binding domain of TERT expressed
in lysate, we assayed for coimmunoprecipitation of a fulllength telomerase RNA bearing a 3⬘ sequence tag. Extension
of the telomerase RNA 3⬘ end does not inhibit activity (data
not shown) or TERT interaction (see below). TERT protein
was mixed with 20 ng of tagged RNA plus a 1-, 5-, or 25-fold
molar excess of competitor RNA relative to the tagged RNA,
which itself was in molar excess of the protein. As a positive
control, untagged full-length telomerase RNA competed the
coimmunoprecipitation of the tagged RNA by TERT (Fig. 4D,
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lanes 1 to 3) or the RNA binding domain of TERT (Fig. 4D,
lanes 7 to 9). Telomerase RNA with the CA15-16GU substitution did not compete the immunoprecipitation of tagged
telomerase RNA by TERT (Fig. 4D, lanes 4 to 6) or the RNA
binding domain of TERT (Fig. 4D, lanes 10 to 12). We conclude that the interaction of the minimized TERT RNA binding domain (amino acids 195 to 516) with the telomerase RNA
is specific and reflects interactions required for stable proteinRNA association in the WT RNP.
The N terminus of hTERT also mediates telomerase RNA
association. We next asked if separation of an independently
functional telomerase RNA binding domain from the RT active site motifs is an evolutionarily conserved feature of
TERTs. To do this, we analyzed the telomerase RNA binding
properties of TERT from human cells. We created a set of
constructs for hTERT expression in vivo (Fig. 5A). Because in
vitro reconstitution of hTERT and hTR in rabbit reticulocyte
lysate is strikingly inefficient compared to reconstitution of
Tetrahymena TERT and telomerase RNA, in vivo reconstitution of the human RNP was used to provide a more robust
assay. Each hTERT expression construct was engineered to
include a Flag epitope tag at the hTERT N terminus. We
tested three progressive C-terminal truncations which removed
RT motifs A to E (amino acids 1 to 656), RT motifs 1 and 2
(amino acids 1 to 617), and motif T (amino acids 1 to 540). One
additional construct was tested which removed the first 325
amino acids as well as all of the RT motifs, while leaving motif
T intact (amino acids 326 to 613). Flag-tagged full-length
hTERT (amino acids 1 to 1132) and hTERT truncations were
expressed by transient transfection of immortal human 293
cells, which contain abundant hTR and telomerase activity.
The interaction of the epitope-tagged hTERT proteins with
endogenous hTR was assayed by Flag antibody immunoprecipitation followed by RNA blot hybridization. As with Tetrahymena TERT, we found that all of the conserved RT motifs
are dispensable for hTERT-hTR interaction (Fig. 5B, hTR
1–451, lanes 2, 4, and 6). Removal of motif T, however, abrogated detectable hTERT-hTR association (Fig. 5B, lane 8).
In contrast, removal of the N-terminal 325 amino acids of
hTERT, including the conserved motif T2, did not similarly inhibit hTERT-hTR association (Fig. 5B, lane 10). The
amount of hTR immunoprecipitated by hTERT 326–613 (Fig.
5B, lane 10) is reduced relative to the other hTERT fragments
(Fig. 5B, lanes 2, 4, and 6). This may be due to the reduced
expression and recovery of this hTERT fragment by immunoprecipitation (Fig. 5C, lane 5). The expression and immunoprecipitation efficiencies of the other hTERT fragments were
comparable (Fig. 5C, lanes 1 to 4, and data not shown).
We have previously demonstrated that two separable regions of hTR each interact independently with hTERT in vivo
and in vitro (26). One of these regions is contained within the
H/ACA domain at the 3⬘ end of hTR (nt 211 to 451), which can
accumulate in vivo at a level comparable to the full-length
molecule (nt 1 to 451). We therefore could test whether the
hTR H/ACA domain alone interacts equally well with fulllength hTERT and each of the hTERT truncations using coexpression by transient transfection (Fig. 5B, hTR 211–451).
We found that the specificity of association of the recombinant
hTR H/ACA domain alone with the hTERT fragments closely
parallels that of full-length endogenous hTR. Thus, the T mo-
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FIG. 5. Evolutionary conservation of TERT-telomerase RNA interaction. (A) hTERT sequence is indicated as a rectangle scaled to amino acid
length with conserved RT and TERT motifs shaded. C- and N-terminal truncations are indicated below; 1–1132 is the full-length protein. The
results of in vivo association assays between hTR and hTERT truncations are indicated by a ⫹ or ⫺ indicating detectable or undetectable
association, respectively. (B and C) Extracts of human 293 cells expressing Flag epitope-tagged full-length hTERT or hTERT truncations were
immunoprecipitated with Flag antibody resin. (B) Total RNA remaining in the immunoprecipitation supernatant (S) and coimmunoprecipitated
with each hTERT (P) was analyzed by RNA blot hybridization for full-length endogenous hTR (hTR 1–451), a coexpressed domain of recombinant
hTR (hTR 211–451), and the endogenous H/ACA snRNA U64. Immunoprecipitates were loaded at a 2⫻ concentration relative to supernatants.
(C) Ten percent of each immunoprecipitate was analyzed by immunoblotting with a polyclonal antibody against an hTERT peptide (27); all
truncations contained this hTERT peptide sequence.

tif, but not amino acids 1 to 325, appears to be required for
association of the hTR H/ACA domain with hTERT. As a
control for the specificity of RNAs immunoprecipitated with
the truncated hTERTs, we assayed for the immunoprecipitation of the box H/ACA small nucleolar RNA, U64. No detectable U64 was precipitated in any of the reactions (Fig. 5B,
lanes 2, 4, 6, 8, and 10).
Telomerase RNA substitutions define the TERT binding
site. Finally, we sought to map the region of Tetrahymena
telomerase RNA that interacts with the TERT RNA binding
domain. The secondary structure of the 159-nt T. thermophila
telomerase RNA is depicted in Fig. 6A, derived from phylogenetic sequence comparison studies (29, 30) and consistent
with in vitro and in vivo chemical modification studies (2, 36).
In addition to nucleotides CA15-16, previous work has revealed a requirement for the C19-G37 base pair at the end of
stem II as important for TERT binding (19). In contrast with
this sequence 5⬘ of the template, stem loops IIIa, IIIb, and IV,
the template sequence (nt 43 to 51), and the adjacent nucleotides UCA38-40, UU41-42, UCU55-57, and C62, can all be
substituted or deleted without substantial impact on stable
TERT interaction (19 and data not shown). To determine if

any other telomerase RNA residues are necessary for TERT
binding, we created telomerase RNA variants with substitutions within the remaining residues between stem loops I and
IIIb.
Depending on the extent of phylogenetic sequence conservation and susceptibility to chemical or enzymatic modification, we substituted one, two, or three positions at a time to
the complementary base(s). Each of these telomerase RNA
variants was transcribed in vitro, purified, and then added to
full-length TERT synthesized in reticulocyte lysate. The reconstituted samples were assayed for telomerase activity. The previously described CA15-16GU substitution and the adjacent
UU17-18AA substitution both inhibited telomerase activity
(Fig. 6B, lanes 3 and 4). Although the C62G substitution (Fig.
6B, lane 7) was inhibitory as previously described (19), the
more conservative C62U telomerase RNA had activity close to
that of WT (Fig. 6B, lane 8). Repeat addition processivity
appeared reduced with the substitution AG58-59UC (Fig. 6B,
lane 5), the same phenotype previously observed with the adjacent substitution UCU55-57AGA (19).
We next tested whether these telomerase RNA variants retained the ability to interact with TERT and the RNA binding
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FIG. 6. Mutational analysis of telomerase RNA. (A) The secondary structure of T. thermophila telomerase RNA is shown based on previous
studies (29, 30). Stems I, II, IIIa, IIIb, and IV are indicated, and the template region is shown in bold. Arrows point to nucleotides which were
mutated in this study. Black arrows indicate nucleotides of telomerase RNA which when substituted induced a strong inhibition of TERT
association. (B) Full-length TERT was expressed in rabbit reticulocyte lysate, mixed with 50 ng of the indicated telomerase RNA, and then assayed
for telomerase activity. (C and D) Thirty nanograms of WT telomerase RNA (lanes 1 and 2) or the telomerase RNA variant indicated (lanes 3
to 11) was coimmunoprecipitated without TERT (lanes 1) or with N-terminally HA-tagged full-length TERT (C) or TERT 195–516 (D).
Coimmunoprecipitated RNA was purified and analyzed by RNA blot hybridization.

domain of TERT. N-terminally HA epitope-tagged full-length
TERT expressed in reticulocyte lysate was combined with 30
ng of each purified telomerase RNA and then immunopurified
using HA antibody resin. A low background level of telomerase RNA was immunoprecipitated by antibody resin alone
(Fig. 6C and D, lanes 1). The CA15-16GU and UU17-18AA
telomerase RNAs were reduced in interaction with TERT or
the TERT RNA binding domain compared with the WT RNA
(Fig. 6C and D, compare lanes 3 and 4 to lane 2), approaching
the background level of RNA associated with antibody resin in
the absence of TERT. The C62G telomerase RNA was also
slightly compromised in TERT interaction, although not as
substantially as CA15-16GU or UU17-18AA RNAs, and none
of the other substitutions had any detectable effect (Fig. 6C

and D, lanes 5 to 11). This is consistent with previous results
(19). These mutational analyses suggest that the CAUU15-18
sequence in particular is important for high-affinity TERT
binding.
The 5ⴕ end of telomerase RNA is sufficient for stable TERT
interaction. Truncation analysis of telomerase RNA has demonstrated that removal of stem loop IV (nt 108 to 159), stem
loop IIIa (nt 77 to 98), or stem loop IIIb (nt 70 to 86) or substitution of distal stem loop II (nt 22 to 34) with a tetraloop
each individually did not affect binding of telomerase RNA to
TERT (19). Based upon this previous study and the implication of nt 15 to 18 as critical for TERT binding, it seemed that
the 3⬘ end of the telomerase RNA might be dispensable for
TERT binding.
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FIG. 7. Truncation analysis of telomerase RNA. Full-length TERT (A) or the RNA binding domain of TERT (B) was expressed and mixed
with 20 ng of a full-length telomerase RNA variant compromised for TERT binding (lanes 1), WT telomerase RNA (lanes 2), or telomerase RNA
deletions (lanes 3 to 7). Coimmunoprecipitated RNA was purified and analyzed by RNA blot hybridization. RNAs of predicted sizes are indicated
by an asterisk. (C) The secondary structure of telomerase RNA. Lines indicate the boundaries of telomerase RNA deletions.

To test this directly, we created expression constructs for a
series of 3⬘ truncations of telomerase RNA. Each telomerase
RNA truncation was transcribed in vitro, gel purified, and then
tested for TERT binding by coimmunoprecipitation. As positive and negative controls for this assay, we found that fulllength telomerase RNA bound to both TERT and the RNA
binding domain of TERT (Fig. 7A and B, lanes 2), whereas
binding of the CA15-16GU variant was strongly inhibited (Fig.
7A and B, lanes 1). Telomerase RNA with deletion of stem
loop IV (Fig. 7A and B, lanes 3) or simultaneous deletion of
stem loops IV and alternate stem loop IIIa and IIIb (Fig. 7A
and B, lanes 4 and 5) all bound TERT at levels comparable to
full-length telomerase RNA. Next, two even more substantial
telomerase RNA truncations were tested which included only
nt 1 to 74 and 1 to 59 of the 159-nt full-length sequence. Both
these shorter RNAs retained high-affinity TERT binding, although there was a possible decrease in the amount of the
shortest 1–59 truncation bound to at least the full-length
TERT protein (Fig. 7A and B, lanes 6 and 7). As expected, all
of the telomerase RNA deletions bound much more poorly to
a TERT fragment lacking the T motif (amino acids 195 to 457)
(data not shown) than to full-length TERT or the RNA binding domain of TERT. This truncation analysis demonstrates
that the 5⬘ end of Tetrahymena telomerase RNA, up to nt 59,
is sufficient for high-affinity RNA binding to full-length TERT
or the isolated TERT RNA binding domain.
DISCUSSION
Catalytically, telomerase is an RT: it copies an RNA template to synthesize one strand of DNA (14). Structurally as

well, the TERT subunit of the telomerase RNP has primary
sequence homology with RTs (21). These similarities aside,
telomerase is a highly atypical polymerase. Telomerase has a
unique substrate specificity for chromosome ends, and unlike
all other RTs, it utilizes only a precisely defined internal RNA
template. Both the template function and the as yet incompletely defined nontemplate functions of the telomerase RNA
make the telomerase enzyme of particular interest as a model
system for understanding the roles of RNA and protein in a
catalytically codependent RNP complex.
We found that even the extreme TERT N and C termini are
required for the catalytic activity of recombinant Tetrahymena
telomerase. The shortest N-terminal and C-terminal truncations tested here had 53 and 85 amino acids of TERT removed,
respectively. This result is somewhat surprising given the minimal evolutionary sequence conservation between even ciliate
TERTs in these regions. Also, truncation of the entire C terminus up to RT motif E in the Saccharomyces cerevisiae TERT
Est2p does not prevent telomere maintenance in vivo (11).
One possible explanation for this difference in the impact of
C-terminal truncation could be that other components of the
yeast telomerase RNP rescue a catalytic deficiency imposed by
C-terminal TERT truncation in vivo. It is also possible that our
C-terminal truncations impacted some aspect of global TERT
protein folding, compromising telomerase RNA binding. However, it seems most likely that the function of the TERT Cterminal region varies among TERTs of different species. A
unigenic evolution approach (11) and a directed mutagenesis
approach (34) investigating the Est2p sequences required for
function in vivo revealed large regions of the Est2p N terminus
that were less tolerant of sequence substitution or deletion.
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The correspondence of these regions of Est2p with specific
amino acids in the Tetrahymena TERT N terminus is difficult to
define, given the relative uncertainty of global sequence alignments in this region.
The main focus of the study described here was to elucidate
how the catalytic telomerase protein and RNA subunits interact. Within the Tetrahymena telomerase RNA, only the RNA
5⬘ end including nt 1 to 59 is necessary for TERT interaction.
Thus, the high-affinity TERT binding site appears to require a
surprisingly small part of the full-length sequence. Our results,
combined with those of a previous study (19), suggest that the
CAUU15-18 sequence of telomerase RNA is the primary site
for TERT binding, with a direct or indirect requirement for at
least the C19-G37 base pair of adjacent stem II. Both fulllength TERT and the TERT RNA binding domain require the
CAUU15-18 sequence in telomerase RNA for high-affinity interaction. The CA15-16 dinucleotide is preferentially protected from chemical modification in the endogenous RNP relative to purified or deproteinized telomerase RNA alone (36).
Our results indicate that this protection is likely to be the direct
consequence of protein association. Notably, a CA(U/C)U sequence is conserved among telomerase RNAs from Tetrahymena
and Paramecium species (22, 23, 29).
Utilizing a truncational analysis, we identified a 322-aminoacid region in the amino terminus of Tetrahymena TERT that
is necessary and sufficient for telomerase RNA binding in vitro.
Although there are potential limitations to our mutagenesis
approach, including the potential for false-negative results due
to misfolding of truncated recombinant proteins, our findings
overall are highly consistent. Full-length TERT and the 322amino-acid TERT RNA binding domain both bind telomerase
RNA with high apparent affinity and similar specificity. We
also identified a 288-amino-acid region of hTERT that is necessary and sufficient for association with hTR in vivo. Our
mapping of Tetrahymena and hTERT telomerase RNA binding domains represents the first identification of independently
functional subregions of TERTs from any species. Notably,
both N-terminal TERT RNA binding domains lack any overlap with the central region of TERT containing the RT active
site motifs. The reiterative use of a fixed internal template thus
appears likely to be programmed from elsewhere than within
the boundaries of a typical polymerase active site.
For Tetrahymena TERT, the telomerase RNA binding domain encompasses two sequence motifs that are conserved
among ciliate TERTs (motifs CP and CP2) and one motif
which is present in all TERTs (motif T). Truncation of either
motif CP2 or motif T inhibited telomerase RNA association. In
a contemporary study, alanine substitution of amino acids in
Tetrahymena TERT motifs CP and T was also found to decrease telomerase RNA binding (5). It is particularly interesting to us that the RNA binding domain of TERT includes both
of the ciliate-specific N-terminal motifs, CP and CP2. First,
because the secondary structures of ciliate telomerase RNAs
are similar, ciliate TERTs are likely to interact with their
respective telomerase RNAs in a related fashion. Second, results from a site-specific mutagenesis study of Tetrahymena
TERT indicate that motif CP2 plays a pivotal role in defining
boundaries of the internal RNA template (24).
For hTERT, we defined a telomerase RNA binding domain
of similar size to the Tetrahymena TERT RNA binding do-
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main, which also precedes the RT active site motifs and contains the conserved motif T. Interestingly, our results predict
that a catalytically inactive hTERT isoform, derived from
mRNA alternative splicing, should contain a completely functional RNA binding domain (18, 32). Thus, the hTERT RNA
binding domain alone may function as a physiologically expressed dominant-negative inhibitor, capable of sequestering
hTR from interaction will full-length hTERT. The similarity
between the Tetrahymena and human telomerase RNA binding
domains is surprising considering the substantial differences
between ciliate and human telomerase RNPs (26). Most obviously, ciliate and vertebrate telomerase RNAs share no conservation of primary sequence and only limited conservation
of secondary structure (7). For the Tetrahymena telomerase
RNA, there appears to be a single TERT binding site that is 5⬘
of the template. In contrast, the human telomerase RNA contains two separable regions which interact independently with
hTERT (26) and has no sequence 5⬘ of the template required
for hTERT-hTR interaction (31 and our unpublished observations). It is therefore particularly striking that removal of
motif T in both Tetrahymena and human TERTs has a similar
impact on telomerase RNA binding. It is possible that the
conserved residues of motif T direct the stable folding of a
novel RNA binding motif and that evolutionarily variable residues outside of this core are responsible for the sequence
specificity of RNA binding.
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